Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
158
days
Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context
AuthorsDaniele Napolitano; Mattia Bozzetti; Rosario Caruso; Monica Guberti; Ileana Frau; Bobbi Smuck; Gionata Fiorino; Franco Scaldaferri; Lucrezia Laterza; Antonio Gasbarrini; Vincenzina Mora
Affiliations1. Scientific Direction – Fondazione Policlinico Universitario IRCCS, Università Cattolica del Sacro Cuore Rome, Rome, Italy; 2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; 3. Direction of Health Professions, ASST Cremona, Cremona, Italy; 4. Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; 5. Health Professions Research and Evidence Transfer Unit, IRCCS MultiMedica, Sesto San Giovanni, Italy; 6. Nursing and Allied Health Professions, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; 7. Ass. Prime Site Director, Strategic Site Solutions EMEA - IQVIA, Milan, Italy; 8. Department of Ophthalmology, Ivey Eye Institute, St. Joseph’s Health Care, London, Canada; 9. Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, Rome, Italy; 10. Centro Malattie dell’Apparato Digerente (CEMAD), Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
210
days
Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?
AuthorsRevathi Ananthakrishnan; Patrick Mitchell; Dong Xi; Gu Mi; Gina D’Angelo; Haijun Ma; Yujun Wu; Philip He
Affiliations1. Bristol-Myers Squibb (BMS), Princeton, USA; 2. AstraZeneca (AZ), Gaithersburg, USA; 3. Gilead, Foster City, USA; 4. Sanofi, Cambridge, USA; 5. Revolution Medicines, Redwood City, USA; 6. Oncolytics Biotech Inc, San Diego, USA; 7. Daiichi Sankyo, Inc, Basking Ridge, USA
182
days
The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials
AuthorsAlexander Przybylski; Björn Holzhauer; Simon Wandel
Affiliations1. Novartis Pharmaceuticals UK Ltd., London, UK; 2. Novartis Pharma AG, Basel, Switzerland
303
days
Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China
AuthorsShuxia Shi; Shangyuan Qin; Qin Yu
Affiliations1. National Drug Clinical Trial Institution of West China Second University Hospital, Sichuan University, Chengdu, China; 2. NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China; 3. Children’s Medicine Key Laboratory of Sichuan Province, Chengdu, China; 4. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China; 5. Department of Pharmacy, Chengdu Fifth People’s Hospital, Chengdu, China
112
days
The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA
AuthorsLing Tang; Songmei Xie; Lijia Yuan; Xiaowen Xu; Xing Ai; Tian Zhao; Zhimin Yang
Affiliations1. Center for Drug Evaluation, National Medical Products Administration, Beijing, The People’s Republic of China
286
days
Utilization of Clinical Evaluation Reports in Japan’s Medical Device Approvals: Insights from Review Data on Approved Devices
AuthorsKoji Yamada; Daisuke Obata; Jun Matsubayashi; Mayumi Yamanaka; Akiko Hinomura; Hiromu Kutsumi; Shin-ya Morita; Shu Kasama
Affiliations1. Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Japan; 2. Asahi Kasei Medical Co., Ltd., Tokyo, Japan; 3. Clinical & Translational Research Center, Kobe University Hospital, Kobe, Japan; 4. Medical Research Support Center, University of Fukui Hospital, Eiheiji-cho, Yoshida-gun, Fukui, Japan; 5. Department of Pharmacotherapeutics, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Japan
156
days
Measuring Centralized Patient Outreach Recruitment Strategies and their Costs in Clinical Trials
AuthorsJennifer Y. Kim; Mary Jo Lamberti; Hana Do
Affiliations1. Tufts Center for the Study of Drug Development (CSDD), Tufts School of Medicine, Boston, USA
183
days
Quantifying the Financial Return on Investment of Risk-Based Quality Management Implementation in Clinical Development
AuthorsAbigail Dirks; Sylviane de Viron; Kenneth McFarlane; Kenneth A. Getz
Affiliations1. Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, USA; 2. Clue Points S.A, Louvain-la-Neuve, Belgium; 3. CluePoints Inc, King of Prussia, USA
44
days
Identifying and Deploying Benchmarks for Clinical Research at Sites
AuthorsRida Momin; Laura Mangiarini; Alexandre Dias Tavares Costa; Carla Peacock; Emaad Shariff; Sara Noorain; Jennifer Preston; Sabah Attar
Affiliations1. Northern Care Alliance NHS Foundation Trust, Greater Manchester, UK; 2. Fondazione Penta ETS, Padova, Italy; 3. Instituto Carlos Chagas (ICC/Fiocruz Paraná), Rio de Janeiro, Brazil; 4. Innovate R Ltd., Manchester, UK; 5. Groundmark Learning, Leamington Spa, UK; 6. University of Liverpool, Liverpool, UK
104
days
Real-World Evidence for Drug Approvals: Moving Toward Greater Regulatory Clarity
AuthorsTala H. Fakhouri; Rasika Kalamegham; Nicole Mahoney; Rose Purcell; Mike D’Ambrosio
Affiliations1. Parexel International, Maryland, USA; 2. Genentech, Washington, DC, USA; 3. Novartis, Rockville, USA; 4. Takeda, Washington, DC, USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days